Bronchopulmonary dysplasia (chronic lung disease of infancy): An update for the pediatrician

Clinical Pediatrics

Volumn 41, Issue 2, 2002, Pages 77-85

  Fernandez Nievas, F ^a   Chernick, V ^a  

^a CHILDREN S HOSPITAL RESEARCH INSTITUTE OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; CROMOGLYCATE DISODIUM; DEXAMETHASONE; DIURETIC AGENT; FUROSEMIDE; PALIVIZUMAB; POTASSIUM CHLORIDE; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT;

ARTERIAL OXYGEN SATURATION; BIRTH WEIGHT; BRAIN GROWTH; CLINICAL FEATURE; CLINICAL TRIAL; DIET THERAPY; DIGESTIVE SYSTEM PERFORATION; DIURETIC THERAPY; HEALTH CARE COST; HUMAN; HYPERPARATHYROIDISM; HYPOKALEMIA; HYPOVENTILATION; HYPOXEMIA; IMAGE ANALYSIS; INFECTION PREVENTION; INFLUENZA; KIDNEY CALCIFICATION; LUNG DYSPLASIA; LUNG MECHANICS; OXYGEN THERAPY; PRIMARY MEDICAL CARE; PROGNOSIS; PULSE OXIMETER; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; TREATMENT OUTCOME; VIRUS INFECTION;

EID: 0036193534     PISSN: 00099228     EISSN: None     Source Type: Journal    
DOI: 10.1177/000992280204100202     Document Type: Review

References (66)

1. Pulmonary disease following respirator therapy of membrane disease
2. Pulmonary fibroplasia following prolonged artificial ventilation of the newborn infant
3. Bronchopulmonary dysplasia: Clinical presentation
4. Abnormal pulmonary outcomes in premature infants: Prediction from oxygen requirement in the neonatal period
5. Treatment of bronchopulmonary dysplasia
6. Bronchopulmonary dysplasia in the 1990s: A review for the pediatrician
7. New consensus definition of bronchopulmonary dysplasia (BPD-DEF) predicts pulmonary and neurodevelopemental outcomes in early infancy
8. NICHD/NHLBI/ORF workshop summary: Bronchopulmonary dysplasia
9. Oxygen plus pressure plus time: The etiology of bronchopulmonary dysplasia
10. The new BPD: An arrest of lung development
11. Bronchoalveolar inflammatory pathophysiology of bronchopulmonary dysplasia
12. Pathophysiology and treatment of bronchopulmonary dysplasia
13. Influence of surfactant replacement on development of bronchopulmonary dysplasia
14. Increased gene expression for VEGF and VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia
15. Hypoxic stabilization of vascular endothelial grown factor mRNA by the RNA binding protein HuR
16. Long-term follow-up of bronchopulmonary dysplasia
17. Home oxygen promotes weight gain in infants with bronchopulmonary dysplasia
18. Noninvasive monitoring of oxygenation in infants and children: Practical considerations and areas of concern
19. Relationship of pulse oximetry to arterial oxygen tension in infants
20. Drug treatment of established BPD
21. Determination of inspired oxygen delivered by nasal cannula in infants with chronic lung disease
22. Randomized, double-blind, controlled trial of long-term diuretic therapy for bronchopulmonary dysplasia
23. Randomized trial of long-term diuretic therapy for infants with oxygen-dependent bronchopulmonary vplasia
24. Short- and long-term effects of furosemide on lung function in infants with bronchopulmonary dysplasia
25. Effect of oral diuretics on pulmonary mechanics in infants with bronchopulmonary dysplasia: Results of a double-blind crossover sequential trial
26. Effect of spironolactone-hydrochlorothiazide on lung function in infants with chronic BPD
27. Nebulized furosemide in infants with bronchopulmonary dysplasia
28. Nephrocalcinosis
29. Nephrocalcinosis in very-low-birth-weight neonates: Family history of kidney stones and ethnicity as independent risk factors
30. Kidney function in very-low-birth-weight infants with furosemide-related renal calcifications at ages 1 to 2 years
31. Nephrocalcinosis in very-low-birth-weight neonates: Sonographic patterns, histologic characteristics, and clinical risk factors
32. Current therapy of bronchopulmonary dysplasia
33. Response to bronchodilators in clinically stable 1-year-old patients with bronchopulmonary dysplasia
34. Ventilator-related pathology in the extremely immature lung
35. Evaluation of airway complications in high-risk pre-term infants: Application of flexible fiberoptic airway endoscopy
36. Effect of altering smooth muscle tone on maximal expiratory flows in patients with tracheomalacia
37. Respiratory responses to salbutamol and dexamethazone in BPD
38. Dexamethasone treatment in preterm infants at risk for bronchopulmonary dysplasia
39. Dexamethasone therapy in infants at risk for chronic lung disease (CLD): A multi-center randomized, double-masked trial
40. Dexamethasone therapy in neonatal chronic lung disease: An international placebo-controlled trial
41. A controlled trial of dexamethasone to prevent bronchopulmonary dysplasia in surfactant-treated infants
42. Adverse effects of early dexamethonase treatment in extremely low birth weight infants
43. Failure of cromolyn sodium to reduce the incidence of bronchopulmonary dysplasia: A pilot study
44. Long-term pulmonary sequelae of severe bronchopulmonary dysplasia
45. The role of inflammation in the pathogenesis of bronchopulmonary dysplasia
46. Association of pulmonary inflammation and increased microvascular permeability during the development of bronchopulmonary dysplasia: A sequential analysis of inflammatory mediators in respiratory fluids of high-risk neonates
47. Amniotic fluid cytokines (interleukin-6, tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-8) and the risk for the development of bronchopulmonary dysplasia
48. Elevation of interleukin-8 and interleukin-6 precedes the influx of neutrophils in tracheal aspirates from pre-term infants who develop bronchopulmonary dysplasia
49. Antioxidants, nutrition, and bronchopulmonary dysplasia
50. Effect of vitamin E on the development of oxygen-induced lung injury in neonates
51. Clinical trial of vitamin A supplementation in infants susceptible to bronchopulmonary dysplasia
52. Inositol supplementation in premature infants with respiratory distress syndrome
53. Use of high-fat formula for pre-mature infants with bronchopulmonary dysplasia: Metabolic, pulmonary, and nutritional studies
54. Influence of energy substrates on respiratory gas exchange during conventional mechanical ventilation of pre-term infants
55. Energy expenditure and severity of respiratory disease in very-low-birth-weight infants receiving long-term ventilatory support
56. Late sequela of bronchopulmonary dysplasia
57. Lung function eight years after neonatal ventilation
58. Longitudinal study of lung function in children following bronchopulmonary dysplasia
59. Long-term pulmonary function studies in children with bronchopulmonary dysplasia: An everchanging saga
60. Effect of pre-term birth on pulmonary function at school age: A prospective controlled study
61. Prevention of respiratory syncytial virus infections: Indications for the use of palivizumab, update on the use of RS-IGIV
62. Prevention and Control of Influenza: Recommendations of the Advisory Committee on Immunization Practices
63. Outcome of respiratory syncytial virus infection and a cost-benefit analysis of prophylaxis
64. Predicting risk for bronchopulmonary dysplasia: Selection criteria for clinical Trials
65. Changing trends in the epidemiology and pathogenesis of neonatal chronic lung disease
66. Variations in practice and outcomes in the Canadian NICU network 1996-1997